Home » Newsletters » BioWorld Science

BioWorld Science

April 22, 2005

View Archived Issues

Fumaric acid esters show promise in the treatment of multiple sclerosis

Greater efficacy found with a duloxetine/PFMT combination in women with SUI

VEGFR-2/EGFR inhibitor displays efficacy in a mouse model of intestinal cancer

Oxoglaucine exhibits promising antienteroviral spectrum

New data on the therapeutic benefits of ropinirole in RLS

AT1-Mas receptor complex: a novel target for cardiovascular disease involving enhanced Ang II action

Intravesical hyaluronic acid proven effective in the management of urinary tract infections

CHIR-12.12 enters phase I

Equetro available for manic and mixed episodes in bipolar I disorder

Phase II/III MEND-CABG trial recommended to continue

New phase II safety study for BLP25 Liposome Vaccine

SkyePharma and Mundipharma enter DepoBupivacaine agreement

Cypher stent approved for MRI scans immediately following implantation

Jazz Pharmaceuticals to acquire Orphan Medical

NDA planned for orBec in iGVHD

Enrollment completed in study of darusentan for resistant systolic hypertension

Insmed studies SomatoKine for HIV-associated lipodystrophy

Genmab reaches SPA agreement for HuMax-CD4 pivotal study

Specific IGF-IR kinase inhibitor inhibits angiogenesis, enhances sensitivity to chemotherapy

Novel small molecule prevents chemotherapy/radiation-induced side effects

PTC Therapeutics identifies compound inhibiting VEGF expression via a novel mechanism

Array BioPharma presents orally active small-molecule inhibitors of EGFR and/or ErbB-2

Fast track designation for terlipressin in type 1 hepatorenal syndrome

European approval for Aclasta in Paget's disease of the bone

Recent patents describe new treatments for inflammatory and autoimmune diseases

New therapeutic agents for gastrointestinal disorders claimed

Theravance presents novel agents for overactive bladder

New therapeutic agents for cardiovascular diseases reported in recent patent literature

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...